IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 33 filers reported holding IMPEL NEUROPHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,684 | -66.1% | 13,218 | 0.0% | 0.00% | – |
Q2 2023 | $16,787 | -9.3% | 13,218 | 0.0% | 0.00% | – |
Q1 2023 | $18,505 | -63.1% | 13,218 | -1.0% | 0.00% | – |
Q4 2022 | $50,082 | -23.0% | 13,355 | 0.0% | 0.00% | – |
Q3 2022 | $65,000 | -31.6% | 13,355 | +30.7% | 0.00% | – |
Q2 2022 | $95,000 | -70.1% | 10,220 | -79.6% | 0.00% | – |
Q1 2022 | $318,000 | -25.4% | 49,985 | +1.3% | 0.00% | – |
Q4 2021 | $426,000 | -30.7% | 49,322 | -2.4% | 0.00% | – |
Q3 2021 | $615,000 | +18.7% | 50,534 | -13.6% | 0.00% | – |
Q2 2021 | $518,000 | – | 58,493 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
LASRY MARC | 408,329 | $1,989,000 | 3.82% |
venBio Partners LLC | 2,759,791 | $13,440,000 | 3.11% |
5AM Venture Management, LLC | 2,884,791 | $14,049,000 | 2.69% |
Vivo Capital, LLC | 2,884,789 | $14,049,000 | 1.55% |
DCF Advisers, LLC | 469,183 | $2,285,000 | 1.48% |
Opaleye Management Inc. | 255,250 | $1,243,000 | 0.51% |
Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $20,142,000 | 0.40% |
EPIQ PARTNERS, LLC | 18,646 | $91,000 | 0.06% |
GILDER GAGNON HOWE & CO LLC | 142,696 | $695,000 | 0.01% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 68,300 | $333,000 | 0.01% |